These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36100960)

  • 1. Isoniazid level and flu-like symptoms during rifapentine-based tuberculosis preventive therapy: A population pharmacokinetic analysis.
    Lee MC; Fujita Y; Muraki S; Huang HL; Lee CH; Wang JY; Ieiri I
    Br J Clin Pharmacol; 2023 Feb; 89(2):714-726. PubMed ID: 36100960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 3. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
    Sterling TR; Moro RN; Borisov AS; Phillips E; Shepherd G; Adkinson NF; Weis S; Ho C; Villarino ME;
    Clin Infect Dis; 2015 Aug; 61(4):527-35. PubMed ID: 25904367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.
    Huang HL; Lee MR; Lee CH; Cheng MH; Lu PL; Sheu CC; Wang JY; Chong IW; Yang JM
    Clin Microbiol Infect; 2024 Nov; 30(11):1410-1417. PubMed ID: 38996972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.
    Huang HL; Lee MR; Cheng MH; Lu PL; Huang CK; Sheu CC; Lai PC; Chen TC; Wang JY; Chong IW
    Clin Infect Dis; 2021 Sep; 73(5):e1064-e1071. PubMed ID: 33215187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection.
    Sadowski C; Belknap R; Holland DP; Moro RN; Chen MP; Wright A; Millet JP; Caylà JA; Scott NA; Borisov A; Gandhi NR
    Clin Infect Dis; 2023 Jun; 76(12):2090-2097. PubMed ID: 36815322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
    Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
    Mathad JS; Savic R; Britto P; Jayachandran P; Wiesner L; Montepiedra G; Norman J; Zhang N; Townley E; Chakhtoura N; Bradford S; Patil S; Popson S; Chipato T; Rouzier V; Langat D; Chalermchockcharoentkit A; Kamthunzi P; Gupta A; Dooley KE
    Clin Infect Dis; 2022 May; 74(9):1604-1613. PubMed ID: 34323955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study.
    Radtke KK; Ernest JP; Zhang N; Ammerman NC; Nuermberger E; Belknap R; Boyd R; Sterling TR; Savic RM
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0170521. PubMed ID: 34606336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection.
    Phaisal W; Jantarabenjakul W; Wacharachaisurapol N; Tawan M; Puthanakit T; Wittayalertpanya S; Chariyavilaskul P
    Int J Infect Dis; 2022 Sep; 122():725-732. PubMed ID: 35868608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
    Yu YY; Tsao SM; Yang WT; Huang WC; Lin CH; Chen WW; Yang SF; Chiou HL; Huang YW
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31892222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
    Jarrett RT; van der Heijden Y; Shotwell MS; Chihota V; Marzinke MA; Chaisson RE; Dooley KE; Churchyard GJ
    Antimicrob Agents Chemother; 2023 Feb; 67(2):e0129722. PubMed ID: 36622148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study.
    Lin SY; Feng JY; Lee CY; Lin YC; Chou YH; Lin KY; Wei YF; Lin SW; Chang CH; Wang PH; Shu CC; Wang JY; Yu CJ
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
    Knoll BM; Nog R; Wu Y; Dhand A
    Infection; 2017 Jun; 45(3):335-339. PubMed ID: 28276008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
    Lin SY; Chiu YW; Lu PL; Hwang SJ; Chen TC; Hsieh MH; Chen YH
    J Microbiol Immunol Infect; 2019 Feb; 52(1):158-162. PubMed ID: 29907535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study Protocol.
    Sekaggya-Wiltshire C; Mbabazi I; Nabisere-Arinaitwe R; Banturaki G; Alinaitwe L; Otalo B; Aber F; Nampala J; Owor R; Bayiga J; Laker Agnes Odongpiny E; Castelnuovo B; Mayito J; Sekadde M; Pasipanodya JG; Turyahabwe S; Zawedde-Muyanja S
    medRxiv; 2024 Jun; ():. PubMed ID: 38853861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.